SORRENTO THERAPEUTICS, INC. Form 8-K (Oct. 7, 2020)

Summary

Current report on Form 8-K for an event dated October 7, 2020, filed by Sorrento Therapeutics, Inc. Under Item 7.01 (Regulation FD Disclosure), the report states that on October 7, 2020 Scilex Holding Company, a majority-owned subsidiary of Sorrento, issued a press release announcing continuous sales growth in ZTlido (lidocaine topical system) of 1.8% from quarter to quarter in 2020. The press release also gives Scilex's expectation that it will complete enrollment of its pivotal "Phase 3" clinical trial for SP-102 (SEMDEXA) in 2020. The release is furnished as Exhibit 99.1 and Henry Ji signed on October 7, 2020.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event
reported): October 7, 2020

SORRENTO THERAPEUTICS, INC.

(Exact Name of Registrant as Specified
in its Charter)

Delaware | 001-36150 | 33-0344842
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.)

4955 Directors Place

San Diego , CA 92121

(Address of Principal Executive Offices)
(Zip Code)

Registrant’s telephone number,
including area code: ( 858 ) 203-4100

N/A

(Former Name, or Former Address, if Changed
Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol | Name of each exchange on which registered
Common Stock, $0.0001 par value | SRNE | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01. Regulation FD Disclosure.

On October 7, 2020, Scilex Holding Company,
a majority-owned subsidiary of Sorrento Therapeutics, Inc. (“Scilex”), issued a press release announcing continuous
sales growth in ZTlido® (lidocaine topical system) 1.8% from quarter to quarter in 2020 and Scilex’s expectation that
it will complete enrollment of its pivotal Phase 3 clinical trial for SP-102 (SEMDEXA™) in 2020. The preliminary financial
information included in the press release is based on Scilex’s current expectations and may be adjusted as a result of, among
other things, completion of customary quarterly review procedures. A copy of the press release is furnished herewith as Exhibit
99.1 to this Current Report on Form 8-K.

The information contained in this Item
7.01 and Exhibit 99.1 furnished as part of Item 9.01 of this Current Report on Form 8-K is being furnished and shall not be deemed
“filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration
statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth
by specific reference to such filing.

Item 9.01. Financial Statements and
Exhibits.

(d) Exhibits.

99.1 | Press Release, dated October 7, 2020.
104 | Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SORRENTO THERAPEUTICS, INC.
Date: October 7, 2020 | By: | /s/ Henry Ji, Ph.D.
Name: Henry Ji, Ph.D.
Title: Chairman of the Board, President and Chief Executive Officer

File and source

File

SEC_SRNE_8-K_filed2020-10-07_0001104659-20-112830.htm

Size

25,571 bytes

SHA-256

b15da5cee5c5b2f5e33d70b5b00adbd4ecaceab6dc34f4460a027e9f75a1cc88

Our copy

SEC_SRNE_8-K_filed2020-10-07_0001104659-20-112830.htm

Original

www.sec.gov